PSMA PET‐targeted biopsy represents a significant advancement in prostate cancer diagnostics, offering higher sensitivity, specificity and accuracy in detecting clinically significant lesions compared to traditional methods. This evidence concerns the gene FOLH1 and prostate cancer.